Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 84,700 shares, an increase of 85.7% from the December 15th total of 45,600 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is presently 0.0 days.

Ensysce Biosciences Stock Performance

ENSC traded down $0.16 during trading on Thursday, reaching $7.00. The company’s stock had a trading volume of 29,675 shares, compared to its average volume of 50,897. The company’s fifty day moving average price is $8.26 and its 200-day moving average price is $6.62. Ensysce Biosciences has a 52-week low of $2.12 and a 52-week high of $30.90. The company has a market capitalization of $9.17 million, a price-to-earnings ratio of -0.26 and a beta of 0.55.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of ($4.50) by $5.55. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The business had revenue of $3.42 million during the quarter, compared to analysts’ expectations of $0.25 million. Equities analysts predict that Ensysce Biosciences will post -12.44 earnings per share for the current year.

Institutional Investors Weigh In On Ensysce Biosciences

A hedge fund recently bought a new stake in Ensysce Biosciences stock. Anson Funds Management LP acquired a new position in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned approximately 11.15% of Ensysce Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 5.63% of the company’s stock.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.